Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

Phase 1

Completed

• Conditions: Oropharyngeal Squamous Cell Carcinoma
• Interventions: Other: Transoral Robotic Surgery (TORS) or Radiotherapy; Other: Chemotherapy and Low-Dose Radiotherapy; Other: Chemotherapy and High-Dose Radiotherapy; Drug: Paclitaxel; Drug: Carboplatin

• Registration Number: NCT04572100
• Lead Sponsor: University of Chicago

Brief Summary

Doctors leading this study will give blood tests to head and neck cancer participants during the beginning of chemotherapy treatment (also known as induction therapy) to see if these blood tests can help predict tumor shrinkage after therapy and reduce the amount of additional radiotherapy or chemotherapy treatment the participant may need. This study will also examine ways to reduce overall side effects of treatment using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-09-17
• Study First Submitted QC: 2020-09-30
• Study Start: 2020-10-01
• Study First Posted: 2020-10-01
• Primary Completion: 2023-01-09
• Study Completion: 2023-01-09
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-06
• Last Update Posted: 2023-07-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Subjects must have clinically confirmed Human papillomavirus(HPV)-positive head and neck squamous cell cancer of the back of the mouth/throat (oropharynx). Confirmed HPV-positive disease of other subsites are uncommon but also eligible.

2. HPV testing must be compliant with the following criteria:

   1. P16INK4a immunohistochemistry (p16 IHC) positivity is sufficient to enroll and initiate treatment (p16 IHC interpretation to follow guidelines by Jordan and Lingen et al72).
   2. p16 IHC positivity is to be validated using an HPV Polymerase chain reaction (PCR - a type of DNA copying method).
   3. HPV PCR must demonstrate HPV16 or HPV18 subtype

3. Availability of greater than 10 unstained 5 micron slides (to be provided to HTRC at the University of Chicago). Patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment on study.

4. Participants must be at least 18 years old.

5. Participants with American Joint Committee on Cancer (AJCC) (8th edition, 2018) N1 (>=3cm), N2-N3 nodal disease or T3-T4 primary tumor.

6. Measurable disease (either primary site or nodal disease) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria.

7. No previous radiation or chemotherapy for a head and neck cancer.

8. No complete surgical resection for a head and neck cancer within 8 weeks of enrollment (although lymph node biopsy including excision of an individual node with presence of residual nodal disease, or surgical biopsy/excision of the tumor with residual measurable disease is acceptable.) No surgical procedures or biopsies will occur after baseline scans are performed and measurable lesions are identified.

9. Eastern Cooperate Oncology Group performance status 0-1

10. Normal organ function clinically confirmed by medical records.

11. Participants must sign a study-specific informed consent form prior to study entry. Participants should have the ability to understand and the willingness to sign a written informed consent document.

12. Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug.

13. Women must not be breastfeeding.

14. Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment.

15. Men who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s).

Exclusion Criteria

1. Any sign of metastatic disease (M1 disease).
2. Non-HPV16/18 subtype
3. Unidentifiable primary site of cancer.
4. Other medical illnesses that may impair the participant's ability to receive therapy or limit survival. This includes but is not limited to ongoing or active infection, immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance. Patients with clinically stable and/or chronically managed medical illnesses that are not symptomatic and/or are not expected to impact treatment on protocol are still eligible (conditions to be reviewed by the PI to confirm eligibility)
5. Prior surgical therapy other than incisional/excisional biopsy or organ-sparing procedures such as debulking of airway-compromising tumors. Residual measurable tumor is required for enrollment as discussed above.
6. Patients receiving other investigational agents.
7. Prior systemic anti-cancer treatment within the last 8 weeks.
8. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or any tumors that are not likely to influence life expectancy in the subsequent 3 years without active treatment.
9. Has known history of, or any evidence of active, non-infectious pneumonitis.
10. Has a history of HIV.
11. Has known active Hepatitis B or hepatitis C. If eradicated, patient is eligible.
12. Has received a live vaccine within 28 days of planned start of study therapy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Group A - Low Risk	Transoral Robotic Surgery (TORS) or Radiotherapy	Participants who have low-risk cancer and significant reduction (greater than 50%) in tumor size following induction therapy will be assigned to this group.
Group B - Intermediate Risk	Chemotherapy and Low-Dose Radiotherapy	Participants who have low-risk cancer and intermediate reduction (30-50%) in tumor size or high-risk cancer with significant reduction (greater than or equal to 50%) in tumor size following induction therapy will be assigned to this group.
Group C - High-Risk	Chemotherapy and High-Dose Radiotherapy	Participants who have high-risk cancer and less than a 50% reduction in their tumor size following induction therapy will be assigned to this group.
Induction Therapy (Carboplatin and Paclitaxel)	Paclitaxel	All study participants will be assigned to this group to first receive induction therapy using a combination of carboplatin and paclitaxel. Participant response to this phase of therapy will determine which group (low-risk, intermediate risk or high-risk) the participant will be in.
Induction Therapy (Carboplatin and Paclitaxel)	Carboplatin	All study participants will be assigned to this group to first receive induction therapy using a combination of carboplatin and paclitaxel. Participant response to this phase of therapy will determine which group (low-risk, intermediate risk or high-risk) the participant will be in.

Primary Outcome Measures

Name	Time	Method
Relationship Between HPV-DNA Found in Participant's Blood and Participant Response to Chemotherapy	16 weeks	To evaluate the relationship (aka correlation) between the amount of HPV-DNA found in a participant's plasma/blood and the participant's response to induction chemotherapy based on how their tumor responds to treatment.
Feasibility of collection of serial HPV-DNA blood samples in patients undergoing treatment for Oropharyngeal Squamous Cell Carcinoma	16 weeks	To determine if it is possible (feasibility) to measure HPV-DNA using blood tests among participants undergoing induction chemotherapy followed by a second round of response-based therapy for their HPV-associated cancer. This feasibility will be determined by measuring the proportion of patients who complete chemotherapy treatment and HPV-DNA assessments.

Secondary Outcome Measures

Name	Time	Method
Changes in Blood Containing HPV-DNA During Response-Based Therapy	16 weeks	To evaluate changes in blood containing HPV-DNA during a second round of chemotherapy (known as response-based chemo-radiotherapy) that will be based on how the participant responded to their first/induction phase of chemotherapy treatment. This outcome will be measured by checking quantitative HPV DNA in plasma with each cycle of induction chemotherapy, weekly during radiation treatment, and following completion of radiation at set time points within the study.
Side Effects of Cisplatin-Based Chemotherapy Treatment	16 weeks	To evaluate the side effects of weekly cisplatin-based treatment in participants receiving chemotherapy followed by a second round of response-based therapy for their HPV-associated cancer.
Tumor Response Among Participants Undergoing Transoral Robotic Surgery	20 weeks	To determine how participant's tumor/cancer responds when they are undergoing Transoral Robotic Surgery (TORS) following induction chemotherapy. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat. Data about how patients' tumors respond in this study will be compared to similar data from a previous study.
Time to Disease Recurrence	5 years	Length of time participants remain without evidence of disease.
Overall Survival	5 years	Length of time until participant death.
Locoregional Control	5 years	Number of participants who experience local control of their primary tumors after treatment.
Distant Control	5 years	Number of participants who experience control of metastatic disease (distant tumors) after treatment.

Trial Locations

Locations (1)

University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States